TrialOrphanet journal of rare diseases2025

A phase 4, open-label, multicenter study of the safety and efficacy of agalsidase beta in Chinese patients with Fabry disease.

Hong Ren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.